Cytokinetics Inc Stock Ownership - Who owns Cytokinetics?

Insider buying vs selling

Have Cytokinetics Inc insiders been buying or selling?
B. Lynne ParshallDirector2024-07-155,000$10.68
B. Lynne ParshallDirector2024-07-155,000$55.82
Robert I. BlumPresident CEO2024-07-105,767$6.67
Robert I. BlumPresident CEO2024-07-1011,500$54.29
Fady Ibraham MalikEVP Research Development2024-07-095,300$55.91
Fady Ibraham MalikEVP Research Development2024-07-095,300$7.96
Fady Ibraham MalikEVP Research Development2024-07-092,000$55.89
Robert Arthur HarringtonDirector2024-07-05253$54.61
B. Lynne ParshallDirector2024-07-015,000$10.68
B. Lynne ParshallDirector2024-07-015,000$54.22

1 of 12

CYTK insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CYTK insiders and whales buy or sell their stock.

CYTK Shareholders

What type of owners hold Cytokinetics Inc stock?
Blackrock Inc11.84%12,414,773$705.03MInstitution
Fmr LLC10.40%10,901,143$619.08MInstitution
Vanguard Group Inc9.53%9,997,076$567.73MInstitution
Michael Schmertzler9.28%9,730,131$552.57MInsider
T Rowe Price Investment Management Inc4.88%5,121,589$290.86MInstitution
Bank Of America Corp4.56%4,777,628$271.32MInstitution
State Street Corp4.31%4,520,358$256.71MInstitution
Wellington Management Group LLP3.80%3,981,460$226.11MInstitution
Price T Rowe Associates Inc2.80%2,930,948$166.45MInstitution
Eastern Capital Ltd2.75%2,883,845$163.77MInsider

1 of 3

CYTK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CYTK88.57%11.43%Net SellingNet Selling
MDGL23.85%76.15%Net BuyingNet Selling
KRYS76.38%23.62%Net SellingNet Selling
VKTX72.41%9.00%Net SellingNet Selling
NUVL70.13%29.87%Net SellingNet Selling

Cytokinetics Stock Ownership FAQ

Who owns Cytokinetics?

Cytokinetics (NASDAQ: CYTK) is owned by 111.24% institutional shareholders, 14.36% Cytokinetics insiders, and 0.00% retail investors. Michael Schmertzler is the largest individual Cytokinetics shareholder, owning 9.73M shares representing 9.28% of the company. Michael Schmertzler's Cytokinetics shares are currently valued at $544.01M.

If you're new to stock investing, here's how to buy Cytokinetics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.